Antigen News and Research

RSS

Researchers offer promise of strategy for curing HIV infection

Researchers have used radioimmunotherapy (RIT) to destroy remaining human immunodeficiency virus (HIV)-infected cells in the blood samples of patients treated with antiretroviral therapy, offering the promise of a strategy for curing HIV infection. Results of the study were presented today at the annual meeting of the Radiological Society of North America (RSNA).

3 Dec 2013

Newly identified protein could prove promising new drug target for AIDS

Researchers have identified a protein that causes loss of function in immune cells combatting HIV. The scientists report in a paper appearing online Dec. 2 in the Journal of Clinical Investigation that the protein, Sprouty-2, is a promising target for future HIV drug development, since disabling it could help restore the cells' ability to combat the virus that causes AIDS.

2 Dec 2013

New biomarkers to improve diagnostics of prostate cancer

New biomarkers will improve diagnostics of endemic diseases in future, such as prostate cancer. Their mission: to recognize the tumor earlier and classify it more precisely - thereby helping avoid unnecessary operations.

2 Dec 2013

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

Ascend Biopharmaceuticals today announces that is has entered into an agreement with 3M Drug Delivery Systems to evaluate 3M’s Toll-Like Receptor 7/8 (TLR7/8) agonist 3M-051 in combination with Ascend’s proprietary cancer vaccine technology. The collaboration will support the creation and preclinical assessment of novel immunotherapy treatments to be potentially used for a number of different solid tumor types.

29 Nov 2013

Health insurance coverage does not increase risky behavior

People with health insurance are more likely to use preventive services such as flu shots and health screenings to reduce their risk of serious illness, but they are no more likely than people without health insurance to engage in risky health behaviors such as smoking or gaining weight, researchers at UC Davis and University of Rochester have found.

27 Nov 2013

UMass Medical School licenses "anti-gal" technology to Agalimmune

The University of Massachusetts Medical School has licensed "anti-gal" technology developed by Professor of Surgery and Medicine Uri Galili, PhD, to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers. Agalimmune is supported by an investment group comprising Loxbridge Research LLP and Animatrix Capital LLP and is based in London and California.

27 Nov 2013

Researchers successfully target T lymphocytes which play key role in body's immune response

Researchers at the University of California, San Diego School of Medicine have successfully targeted T lymphocytes - which play a central role in the body's immune response - with another type of white blood cell engineered to synthesize and deliver bits of non-coding RNA or microRNA (miRNA).

26 Nov 2013

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Agalimmune Ltd, a biopharmaceutical company, has been created to develop innovative immunotherapeutics for the treatment of cancer, with a focus on solid tumours.

26 Nov 2013

Novel urinary antigen test boosts S. pneumoniae CAP detection

Research published in the European Respiratory Journal shows that addition of a serotype-specific urinary antigen detection test to existing diagnostic methods can increase the detection of Streptococcus pneumoniae community-acquired pneumonia by over a third.

25 Nov 2013

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.

25 Nov 2013

Scientists find link between airborne allergies and risk of blood cancers in women

A team of scientists looking into the interplay of the immune system and cancer have found a link between a history of airborne allergies - in particular to plants, grass and trees - with risk of blood cancers in women.

25 Nov 2013

Covagen, TRL expand research collaboration to generate bispecific FynomAb

Covagen and Tanabe Research Laboratories U.S.A, Inc., a fully owned subsidiary of Mitsubishi Tanabe Pharma Corporation, today announced that they expanded their strategic research collaboration. MTPC and TRL have nominated a first bispecific FynomAb for formal preclinical development which triggered an undisclosed milestone payment. MTPC and TRL also exercised an option for a second bispecific FynomAb program based on the parties' research and licensing agreement signed in October 2012.

21 Nov 2013

DNA vaccine demonstrates potential to prevent and treat deadly MERS coronavirus

Inovio Pharmaceuticals, Inc. announced today that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, demonstrating the potential for a SynCon DNA vaccine to prevent and treat this deadly virus.

20 Nov 2013

Generex Biotechnology provides update on Phase II trial of AE37 breast cancer vaccine

Generex Biotechnology Corporation today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. A previously released positive interim analysis showed a strong trend toward reduced relapse in breast cancer patients receiving the AE37 vaccine.

18 Nov 2013

Medix Biochemica to launch antibody production services for IVD assays at MEDICA 2013

Medix Biochemica, producer of monoclonal antibodies for the global IVD industry and diagnostic rapid tests, is presenting its MedixMAB by Design and MedixMAB Manufacturing antibody production services to the European market at MEDICA 2013, Dusseldorf, Germany, 20-23 November, Hall 3, Stand F44.

14 Nov 2013

CD137 T cell activation molecule can help identify rare antitumor T cells in human cancers

Patients with tumors that contain increased numbers of T lymphocytes generally survive longer than those with tumors without T-cell involvement, suggesting that T cells with potent antitumor function naturally exist in cancer and control tumor progression. With the exception of melanoma, it has been difficult to identify and isolate the tumor-reactive T cells from common cancers, however, the ability to do so could be used to fight a patient's own cancer.

14 Nov 2013

immatics, Roche enter into cancer vaccine and immunotherapy deal

immatics biotechnologies GmbH and Roche today announced a strategic research and development collaboration covering multiple cancer vaccines and immunotherapeutics.

13 Nov 2013

Lifestyle changes boost QoL during long-term ADT

A study shows that a lifestyle intervention, involving an exercise program and dietary advice, improves disease-specific quality of life in sedentary men with advanced prostate cancer who are receiving long-term androgen-deprivation therapy.

11 Nov 2013

New 'clinical score' test for patients with sore throats reduces antibiotics usage nearly 30%

A new 'clinical score' test for patients with sore throats could reduce the amount of antibiotics prescribed and result in patients feeling better more quickly, research in the British Medical Journal shows.

11 Nov 2013

Cancer pioneer James Allison wins 2013 Innovations Award for bioscience

For basic science research that opened a completely new approach for treating cancer, The Economist has named James Allison, Ph.D., professor and chair of Immunology at The University of Texas MD Anderson Cancer Center, as its 2013 Innovations Award winner in Bioscience.

8 Nov 2013

Antigen News and Research

Researchers offer promise of strategy for curing HIV infection

Newly identified protein could prove promising new drug target for AIDS

New biomarkers to improve diagnostics of prostate cancer

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

Health insurance coverage does not increase risky behavior

UMass Medical School licenses "anti-gal" technology to Agalimmune

Researchers successfully target T lymphocytes which play key role in body's immune response

Agalimmune established to develop innovative immunotherapeutics for treatment of cancer

Novel urinary antigen test boosts S. pneumoniae CAP detection

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Scientists find link between airborne allergies and risk of blood cancers in women

Covagen, TRL expand research collaboration to generate bispecific FynomAb

DNA vaccine demonstrates potential to prevent and treat deadly MERS coronavirus

Generex Biotechnology provides update on Phase II trial of AE37 breast cancer vaccine

Medix Biochemica to launch antibody production services for IVD assays at MEDICA 2013

CD137 T cell activation molecule can help identify rare antitumor T cells in human cancers

immatics, Roche enter into cancer vaccine and immunotherapy deal

Lifestyle changes boost QoL during long-term ADT

New 'clinical score' test for patients with sore throats reduces antibiotics usage nearly 30%

Cancer pioneer James Allison wins 2013 Innovations Award for bioscience

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News